antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2024-69-7-8-53-66antibiotics-1162Research ArticleОБЗОРЫREVIEWSВозможности антибактериальной терапии инфекций, вызванных карбапенемоустойчивыми Acinetobacter baumanniiAntibacterial Therapy Options for Infections Caused by Carbapenem-Resistant Acinetobacter baumanniihttps://orcid.org/0009-0009-6559-7892ГончароваА. Р.GoncharovaA. R.

Гончарова Алина Рамилевна — лаборант-исследователь, Федеральное государственное бюджетное учреждение «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства»; ассистент кафедры, Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России; младший научный сотрудник, Федеральное бюджетное учреждение науки «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека

WOS Researcher ID: JNR-9369-2023

Санкт-Петербург

Alina R. Goncharova — laboratory assistant-researcher, Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; department assistant, North-Western State Medical University named after I. I. Mechnikov of the Ministry of Health of the Russian Federation; junior researcher, Saint-Petersburg Pasteur Institute of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

WOS Researcher ID: JNR-9369-2023

Saint Petersburg

guestvv11@gmail.comhttps://orcid.org/0000-0002-3480-8089ГостевВ. В.GostevV. V.

Гостев Владимир Валерьевич — к. б. н., старший научный сотрудник, Федеральное государственное бюджетное учреждение «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства»; доцент кафедры, Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России

WOS Researcher ID: P-1949-2016

Scopus Author ID: 55614534400

Санкт-Петербург

Vladimir V. Gostev — Ph. D. in Biology, Senior Researcher, Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; Associate Professor of the Department, North-Western State Medical University named after I. I. Mechnikov of the Ministry of Health of the Russian Federation

WOS Researcher ID: P-1949-2016

Scopus Author ID: 55614534400

Saint Petersburg

https://orcid.org/0000-0002-6097-5091ГончаровН. Е.GoncharovN. E.

Гончаров Никита Евгеньевич — младший научный сотрудник, Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России; Федеральное бюджетное учреждение науки «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека

WOS Researcher ID: IAQ-4804-2023

Scopus Author ID: 57225153032

Санкт-Петербург

Nikita E. Goncharov — Junior Researcher, North-Western State Medical University named after I. I. Mechnikov of the Ministry of Health of the Russian Federation; Saint-Petersburg Pasteur Institute of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

WOS Researcher ID: IAQ-4804-2023

Scopus Author ID: 57225153032

Saint Petersburg

https://orcid.org/0000-0003-1419-9068КалиногорскаяО. С.KalinogorskayaO. S.

Калиногорская Ольга Серафимовна — к. м. н., научный сотрудник

WOS Researcher ID: AAW-3832-2020

Scopus Author ID: 56525317800

Санкт-Петербург

Olga S. Kalinogorskaya — Ph. D. in Medicine, Researcher, Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency

WOS Researcher ID: AAW-3832-2020

Scopus Author ID: 56525317800

Saint Petersburg

https://orcid.org/0000-0003-2732-5676ГладышевН. С.GladyshevN. S.

Гладышев Никита Сергеевич — научный сотрудник

WOS Researcher ID: S-9158-2018

Scopus Author ID: 57392981200

Санкт-Петербург

Nikita S. Gladyshev — researcher, Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution «Petrovsky National Research Centre of Surgery»

WOS Researcher ID: S-9158-2018

Scopus Author ID: 57392981200

Moscow

ФГБУ «Детский научно-клинический центр инфекционных болезней ФМБА России»; ФГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова Минздрава России; ФБУН НИИ эпидемиологии и микробиологии имени ПастераРоссияPediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; North-Western State Medical University named after I. I. Mechnikov; Saint-Petersburg Pasteur InstituteRussian FederationФГБУ «Детский научно-клинический центр инфекционных болезней ФМБА России»; ФГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова Минздрава РоссииРоссияPediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency; North-Western State Medical University named after I. I. MechnikovRussian FederationФГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова Минздрава России; ФБУН НИИ эпидемиологии и микробиологии имени ПастераРоссияNorth-Western State Medical University named after I. I. MechnikovRussian FederationФГБОУ ВО Северо-Западный государственный медицинский университет им. И. И. Мечникова Минздрава РоссииРоссияNorth-Western State Medical University named after I. I. MechnikovRussian FederationНИИ морфологии человека им. академика А. П. Авцына ГНЦ РФ ФГБНУ РНЦХ им. академика Б. В. ПетровскогоРоссияAvtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution «Petrovsky National Research Centre of Surgery»Russian Federation202421112024697-85366Copyright © Гончарова А.Р., Гостев В.В., Гончаров Н.Е., Калиногорская О.С., Гладышев Н.С., 20242024Гончарова А.Р., Гостев В.В., Гончаров Н.Е., Калиногорская О.С., Гладышев Н.С.Goncharova A.R., Gostev V.V., Goncharov N.E., Kalinogorskaya O.S., Gladyshev N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1162

В обзоре представлены актуальные схемы терапии инфекций, ассоциированных с карбапенем-устойчивыми Acinetobacter baumannii, являющимися ведущими нозокомиальными патогенами, проявляющими множественную лекарственную устойчивость к доступным антибактериальным препаратам. На сегодняшний день широко использующиеся бета-лактамные антибиотики, в том числе карбапенемы, утратили свою эффективность в борьбе с ацинетобактерными инфекциями, а новые антибиотики остаются малодоступными для пациентов. В связи с чем единственной мерой борьбы с антибиотикорезистентностью карбапенем-устойчивых A. baumannii является оценка активности комбинированной терапии in vitro и in vivo, что представляет особый интерес для отечественных и зарубежных исследователей.

The review presents current treatment regimens for infections associated with carbapenem-resistant Acinetobacter baumannii, which are leading nosocomial pathogens exhibiting multidrug resistance to available antibacterial drugs. To date, widely used beta-lactam antibiotics, including carbapenems, have lost their effectiveness in combating acinetobacter infections, while new antibiotics remain poorly available to patients. Therefore, the only measure to combat the antibiotic resistance of carbapenem-resistant A. baumannii is to evaluate the efficiency of combination therapy in vitro and in vivo, which is of particular interest to Russian and foreign researchers.

карбапенемоустойчивые A. baumanniiкомбинированная терапиямножественная устойчивость к антибактериальным препаратамcarbapenem-resistant A. baumanniicombination therapymultidrug resistanceReferencesAntimicrobial Resistance, Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399 (10325): 629–655. doi: 10.1136/ebnurs-2022-103540. Online ahead of print.Antimicrobial Resistance, Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399 (10325): 629–655. doi: 10.1136/ebnurs-2022-103540. Online ahead of print.Collaborators, G.B.D.A.R., Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400 (10369): 2221–2248. doi: 10.1016/S0140-6736(22)02185-7.Collaborators, G.B.D.A.R., Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400 (10369): 2221–2248. doi: 10.1016/S0140-6736(22)02185-7.Mea H.J., Yong P.V.C., Wong E.H. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiol Res. 2021; 247: 126722. doi: 10.1016/j.micres.2021.126722.Mea H.J., Yong P.V.C., Wong E.H. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiol Res. 2021; 247: 126722. doi: 10.1016/j.micres.2021.126722.Wilharm G., Skiebe E., Lopinska A. et al. On the ecology of Acinetobacter baumannii — jet stream rider and opportunist by nature. bioRxiv. 2024; 2024.01.15.572815.Wilharm G., Skiebe E., Lopinska A. et al. On the ecology of Acinetobacter baumannii — jet stream rider and opportunist by nature. bioRxiv. 2024; 2024.01.15.572815.Mancuso G., Midiri A., Gerace E., Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens, 2021. 10 (10): 1310. doi: 10.3390/pathogens10101310.6.Mancuso G., Midiri A., Gerace E., Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens, 2021. 10 (10): 1310. doi: 10.3390/pathogens10101310.6.EUCAST. Expected Resistant Phenotypes. 2023; Available from: https://www.eucast.org/expert_rules_and_expected_phenotypes.EUCAST. Expected Resistant Phenotypes. 2023; Available from: https://www.eucast.org/expert_rules_and_expected_phenotypes.Butler M.S., Gigante V., Sati H. et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022. 66 (3): e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10.Butler M.S., Gigante V., Sati H. et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022. 66 (3): e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10.Jung S.Y., Lee S.H., Lee S.Y. et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care 2017; 21 (1): 319. doi: 10.1186/s13054-017-1916-6.Jung S.Y., Lee S.H., Lee S.Y. et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care 2017; 21 (1): 319. doi: 10.1186/s13054-017-1916-6.Paul M., Carrara E., Retamar P. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022; 28 (4): 521–547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.Paul M., Carrara E., Retamar P. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022; 28 (4): 521–547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.Tamma P.D., Aitken S.L., Bonomo R.A. et al. Infectious Diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023; ciad4228. doi: 10.1093/cid/ciad428.Tamma P.D., Aitken S.L., Bonomo R.A. et al. Infectious Diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023; ciad4228. doi: 10.1093/cid/ciad428.Kanj S.S., Bassetti M., Kiratisin P. et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022; 60 (3): 106633. doi: 10.1016/j.ijantimicag.2022.106633.Kanj S.S., Bassetti M., Kiratisin P. et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022; 60 (3): 106633. doi: 10.1016/j.ijantimicag.2022.106633.Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019; 69 (Suppl 7): S565–S575. doi: 10.1093/cid/ciz830.Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019; 69 (Suppl 7): S565–S575. doi: 10.1093/cid/ciz830.Shields R.K., Paterson D.L., Tamma P.D. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis. 2023; 76 (Suppl 2): S179–S193. doi: 10.1093/cid/ciad094.Shields R.K., Paterson D.L., Tamma P.D. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis. 2023; 76 (Suppl 2): S179–S193. doi: 10.1093/cid/ciad094.Penwell W.F., Shapiro A.B., Giacobbe R.A. et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59(3): 1680–9. doi: 10.1128/AAC.04808-14.Penwell W.F., Shapiro A.B., Giacobbe R.A. et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59(3): 1680–9. doi: 10.1128/AAC.04808-14.Wang L., Chen Y., Han R., Huang Z., Zhang X., Hu F., Yang F. Sulbactam enhances in vitro activity of beta-lactam antibiotics against Acinetobacter baumannii. Infect Drug Resist, 2021. 14: p. 3971–3977. doi: 10.2147/IDR.S332160.Wang L., Chen Y., Han R., Huang Z., Zhang X., Hu F., Yang F. Sulbactam enhances in vitro activity of beta-lactam antibiotics against Acinetobacter baumannii. Infect Drug Resist, 2021. 14: p. 3971–3977. doi: 10.2147/IDR.S332160.Chen H., Liu Q., Chen Z., Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis. J Infect Chemother. 2017; 23 (5): 278–285. doi: 10.1016/j.jiac.2017.01.005.Chen H., Liu Q., Chen Z., Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis. J Infect Chemother. 2017; 23 (5): 278–285. doi: 10.1016/j.jiac.2017.01.005.Krizova L., Poirel L., Nordmann P., Nemec A. TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J Antimicrob Chemother, 2013; 68 (12): 2786–91. doi: 10.1093/jac/dkt275.Krizova L., Poirel L., Nordmann P., Nemec A. TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J Antimicrob Chemother, 2013; 68 (12): 2786–91. doi: 10.1093/jac/dkt275.Drawz S.M., Bonomo R.A. Three Decades of {beta}-lactamase inhibitors. Clin. Microbiol. Rev. 2010; 23 (1): 160–201. doi: 10.1128/CMR.00037-09.Drawz S.M., Bonomo R.A. Three Decades of {beta}-lactamase inhibitors. Clin. Microbiol. Rev. 2010; 23 (1): 160–201. doi: 10.1128/CMR.00037-09.Kuo S.C., Lee Y.-T, Lauderdale T.-L., et al. Contribution of Acinetobacterderived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front Microbiol. 2015; 6: 231. doi: 10.3389/fmicb.2015.00231.Kuo S.C., Lee Y.-T, Lauderdale T.-L., et al. Contribution of Acinetobacterderived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front Microbiol. 2015; 6: 231. doi: 10.3389/fmicb.2015.00231.Yang Y., Xu Q., Li T., et al. OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2019; 63 (1). e01676–18. doi: 10.1128/AAC.01676-18.Yang Y., Xu Q., Li T., et al. OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2019; 63 (1). e01676–18. doi: 10.1128/AAC.01676-18.Liu J., Shu Y., Zhu F., Feng B., Zhang Z., Liu L., Wang G. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drugresistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021; 24: 136–147. doi: 10.1016/j.jgar.2020.08.021.Liu J., Shu Y., Zhu F., Feng B., Zhang Z., Liu L., Wang G. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drugresistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021; 24: 136–147. doi: 10.1016/j.jgar.2020.08.021.Bian X., Liu X., Feng M. et al. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2021; 57 (2): 106271. doi: 10.1016/j.ijantimicag.2020.106271.Bian X., Liu X., Feng M. et al. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2021; 57 (2): 106271. doi: 10.1016/j.ijantimicag.2020.106271.Srisakul S., Wannigama D.L., Higgins P.G. et al. Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin-sulbactam combination therapy. Sci Rep. 2022; 12 (1): 11390. doi: 10.1038/s41598-022-15386-1.Srisakul S., Wannigama D.L., Higgins P.G. et al. Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin-sulbactam combination therapy. Sci Rep. 2022; 12 (1): 11390. doi: 10.1038/s41598-022-15386-1.Yahav D.,Giske C., Gramatniece A., Abodakpi H., Tam V.H., Leibovici L. New beta-Lactam-beta-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34 (1): e00115. doi: 10.1128/CMR.00115-20..Yahav D.,Giske C., Gramatniece A., Abodakpi H., Tam V.H., Leibovici L. New beta-Lactam-beta-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34 (1): e00115. doi: 10.1128/CMR.00115-20..Rodriguez C.H., Brune A., Nastro M., Vay C., Famiglietti A. In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. 2020; 69 (7): 928–931. doi: 10.1099/jmm.0.001211.Rodriguez C.H., Brune A., Nastro M., Vay C., Famiglietti A. In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. 2020; 69 (7): 928–931. doi: 10.1099/jmm.0.001211.Pasteran F., Cedano J., Baez M., et al. A new twist: the combination of sulbactam/avibactam enhances sulbactam activity against carbapenem-resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel), 2021; 10 (5): 577. doi: 10.3390/antibiotics10050577.Pasteran F., Cedano J., Baez M., et al. A new twist: the combination of sulbactam/avibactam enhances sulbactam activity against carbapenem-resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel), 2021; 10 (5): 577. doi: 10.3390/antibiotics10050577.Dudoignon E., Camelena F., Lafaurie M., et al. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit. Eur J Clin Microbiol Infect Dis. 2024; 43 (7): 1453–1459. doi: 10.1007/s10096-024-04840-9.Dudoignon E., Camelena F., Lafaurie M., et al. Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit. Eur J Clin Microbiol Infect Dis. 2024; 43 (7): 1453–1459. doi: 10.1007/s10096-024-04840-9.Cedano J., Baez M., Pasteran F. et al. Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. Front Cell Infect Microbiol. 2022; 12: 918868. doi: 10.3389/fcimb.2022.918868.Cedano J., Baez M., Pasteran F. et al. Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. Front Cell Infect Microbiol. 2022; 12: 918868. doi: 10.3389/fcimb.2022.918868.McLeod S.M., Donneli J.P., Narayanan N., Mills J.P., Kaye K.S. Sulbactam-durlobactam: a beta-lactam/beta-lactamase inhibitor combination targeting Acinetobacter baumannii. Future Microbiol. 2024; 19 (7)) 563–576. doi: 10.2217/fmb-2023-0248.McLeod S.M., Donneli J.P., Narayanan N., Mills J.P., Kaye K.S. Sulbactam-durlobactam: a beta-lactam/beta-lactamase inhibitor combination targeting Acinetobacter baumannii. Future Microbiol. 2024; 19 (7)) 563–576. doi: 10.2217/fmb-2023-0248.Shapiro A.B., Moussa S.H., McLeod S.M., Durand-Reville T., Miller A. Durlobactam, a new diazabicyclooctane beta-lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam. Front Microbiol. 2021; 12: 709974. doi: 10.3389/fmicb.2021.709974.Shapiro A.B., Moussa S.H., McLeod S.M., Durand-Reville T., Miller A. Durlobactam, a new diazabicyclooctane beta-lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam. Front Microbiol. 2021; 12: 709974. doi: 10.3389/fmicb.2021.709974.Kaye K.S., Shorr A.F., Wunderink R.G. et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023; 23 (9): 1072–1084. doi: 10.1016/S1473-3099(23)00184-6.Kaye K.S., Shorr A.F., Wunderink R.G. et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023; 23 (9): 1072–1084. doi: 10.1016/S1473-3099(23)00184-6.Giuliano S., Sbrana F., Tascini C. Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex. Lancet Infect Dis. 2023; 23 (8): e274. doi: 10.1016/S1473-3099(23)00422-X.Giuliano S., Sbrana F., Tascini C. Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex. Lancet Infect Dis. 2023; 23 (8): e274. doi: 10.1016/S1473-3099(23)00422-X.Seifert H., Muller C., Stefanic D., Higgins P.G., Miller A., Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2020; 75 (9): 2616–621. doi: 10.1093/jac/dkaa208.Seifert H., Muller C., Stefanic D., Higgins P.G., Miller A., Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2020; 75 (9): 2616–621. doi: 10.1093/jac/dkaa208.Karlowsky J.A., Hackel M., McLeod S.M., Miller A. In vitro activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrob Agents Chemother. 2022; 66 (9): e0078122. doi: 10.1128/aac.00781-22.Karlowsky J.A., Hackel M., McLeod S.M., Miller A. In vitro activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrob Agents Chemother. 2022; 66 (9): e0078122. doi: 10.1128/aac.00781-22.Principe L., Bella S.D., Conti J., Perilli M., Piccirilli A., Mussini C., Decorti G. Acinetobacter baumannii resistance to sulbactam/durlobactam: a systematic review. Antibiotics (Basel). 2022; 11 (12): 1793. doi: 10.3390/antibiotics11121793.Principe L., Bella S.D., Conti J., Perilli M., Piccirilli A., Mussini C., Decorti G. Acinetobacter baumannii resistance to sulbactam/durlobactam: a systematic review. Antibiotics (Basel). 2022; 11 (12): 1793. doi: 10.3390/antibiotics11121793.McLeod S.M., Carter N.M., Bradford P.A., Miller A.A. In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex. Diagn Microbiol Infect Dis. 2024; 109 (3): 116344. doi: 10.1016/j.diagmicrobio.2024.116344.McLeod S.M., Carter N.M., Bradford P.A., Miller A.A. In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex. Diagn Microbiol Infect Dis. 2024; 109 (3): 116344. doi: 10.1016/j.diagmicrobio.2024.116344.Moussa S.H., Shapiro A.H., McLeod S.M. et al. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2023; 67 (11): e0066523. doi: 10.1128/aac.00665-23.Moussa S.H., Shapiro A.H., McLeod S.M. et al. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2023; 67 (11): e0066523. doi: 10.1128/aac.00665-23.Grossman T.H. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med, 2016; 6 (4): a025387. doi: 10.1101/cshperspect.a025387.Grossman T.H. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med, 2016; 6 (4): a025387. doi: 10.1101/cshperspect.a025387.LaPlante K.L., Dhand A., Wright K., Lauterio M. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Ann Med. 2022; 54 (1): 1686–1700. doi: 10.1080/07853890.2022.2085881.LaPlante K.L., Dhand A., Wright K., Lauterio M. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Ann Med. 2022; 54 (1): 1686–1700. doi: 10.1080/07853890.2022.2085881.Sun C., Yu Y., Hua X. Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front Cell Infect Microbiol. 2023; 13: 1141490. doi: 10.3389/fcimb.2023.1141490.Sun C., Yu Y., Hua X. Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front Cell Infect Microbiol. 2023; 13: 1141490. doi: 10.3389/fcimb.2023.1141490.Ni W., Han Y., Zhao J., Wei C., Cui J., Wang R., Liu Y. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents, 2016; 47 (2): 107–16. doi: 10.1016/j.ijantimicag.2015.11.011.Ni W., Han Y., Zhao J., Wei C., Cui J., Wang R., Liu Y. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents, 2016; 47 (2): 107–16. doi: 10.1016/j.ijantimicag.2015.11.011.Sodeifian F., Zangiabadian M., Arabpour E. et al. Tigecycline-containing regimens and multi drug-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Microb Drug Resist. 2023; 29 (8): 344–359. doi: 10.1089/mdr.2022.0248.Sodeifian F., Zangiabadian M., Arabpour E. et al. Tigecycline-containing regimens and multi drug-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Microb Drug Resist. 2023; 29 (8): 344–359. doi: 10.1089/mdr.2022.0248.Jo J., Ko K.S. Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii. Microbiol Spectr. 2021; 9 (2): e0101021. doi: 10.1128/Spectrum.01010-21.Jo J., Ko K.S. Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii. Microbiol Spectr. 2021; 9 (2): e0101021. doi: 10.1128/Spectrum.01010-21.De Pascale G., Lisi L., Ciotti G.M.P., Vallecoccia M.S. et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020; 10 (1): 94. doi: 10.1186/s13613-020-00715-2.De Pascale G., Lisi L., Ciotti G.M.P., Vallecoccia M.S. et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020; 10 (1): 94. doi: 10.1186/s13613-020-00715-2.Xie J., Roberts J.A., Alobaid A.S. et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother. 2017; 61 (8): e00345–17. doi: 10.1128/AAC.00345-17.Xie J., Roberts J.A., Alobaid A.S. et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother. 2017; 61 (8): e00345–17. doi: 10.1128/AAC.00345-17.Kengkla K., Kongpakwattana R., Saokaew S., Apisarnthanarak A., Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018; 73 (1): 22–32. doi: 10.1093/jac/dkx368.Kengkla K., Kongpakwattana R., Saokaew S., Apisarnthanarak A., Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018; 73 (1): 22–32. doi: 10.1093/jac/dkx368.Wu H., Feng H., He L., Zhang H., Xu P. In vitro activities of tigecycline in combination with amikacin or colistin against carbapenem-resistant Acinetobacter baumannii. Appl Biochem Biotechnol. 2021; 193 (12): 3867–3876. doi: 10.1007/s12010-021-03664-z.Wu H., Feng H., He L., Zhang H., Xu P. In vitro activities of tigecycline in combination with amikacin or colistin against carbapenem-resistant Acinetobacter baumannii. Appl Biochem Biotechnol. 2021; 193 (12): 3867–3876. doi: 10.1007/s12010-021-03664-z.Deng Y., Chen L., Yue M., Huang X., Yang Y., Yu H. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect Dis. 2022; 22 (1): 795. doi: 10.1186/s12879-022-07778-5.Deng Y., Chen L., Yue M., Huang X., Yang Y., Yu H. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect Dis. 2022; 22 (1): 795. doi: 10.1186/s12879-022-07778-5.Greig S.L., Scott L.J. Intravenous minocycline: a review in Acinetobacter infections. Drugs. 2016; 76 (15): 1467–1476. doi: 10.1007/s40265-016-0636-6.Greig S.L., Scott L.J. Intravenous minocycline: a review in Acinetobacter infections. Drugs. 2016; 76 (15): 1467–1476. doi: 10.1007/s40265-016-0636-6.Asadi A., Abdi M., Kouhsari E. et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future. J Glob Antimicrob Resist. 2020; 22: 161–174. doi: 10.1016/j.jgar.2020.01.022.Asadi A., Abdi M., Kouhsari E. et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future. J Glob Antimicrob Resist. 2020; 22: 161–174. doi: 10.1016/j.jgar.2020.01.022.Castanheira M., Mendes R.E., Jones R.N. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014; 59: Suppl 6: S367–373. doi: 10.1093/cid/ciu706.Castanheira M., Mendes R.E., Jones R.N. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014; 59: Suppl 6: S367–373. doi: 10.1093/cid/ciu706.Zilberberg, M.D., Kollef M.H., Shorr A.F. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. J Hosp Med. 2016; 11 (1): 21–26. doi: 10.1002/jhm.2477.Zilberberg, M.D., Kollef M.H., Shorr A.F. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. J Hosp Med. 2016; 11 (1): 21–26. doi: 10.1002/jhm.2477.Tarnberg M., Nilsson L.E., Dowzicky M.J. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010–2014. Int J Infect Dis. 2016; 49: 141–148. doi: 10.1016/j.ijid.2016.06.016. Epub 2016 Jun 22.Tarnberg M., Nilsson L.E., Dowzicky M.J. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010–2014. Int J Infect Dis. 2016; 49: 141–148. doi: 10.1016/j.ijid.2016.06.016. Epub 2016 Jun 22.Flamm R.K., Shortridge D., Castanheira M., Sader H.S., Pfaller M.A. In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob Agents Chemother. 2019; 63 (11): e01154. doi: 10.1128/AAC.01154-19.Flamm R.K., Shortridge D., Castanheira M., Sader H.S., Pfaller M.A. In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob Agents Chemother. 2019; 63 (11): e01154. doi: 10.1128/AAC.01154-19.Fragkou P.C., Poulakou G., Blizou A. et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. microorganisms. 2019; 7 (6): 159. doi: 10.3390/microorganisms7060159.Fragkou P.C., Poulakou G., Blizou A. et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. microorganisms. 2019; 7 (6): 159. doi: 10.3390/microorganisms7060159.Chandran S., Manokaran Y., Vijayakuma S. et al. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2023; 42 (5): 645–651. doi: 10.1007/s10096-023-04583-z.Chandran S., Manokaran Y., Vijayakuma S. et al. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2023; 42 (5): 645–651. doi: 10.1007/s10096-023-04583-z.Rodriguez C.H., Nastro M., Vay C., Famiglietti A. In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. J Med Microbiol. 2015; 64 (10): 1196–1200. doi: 10.1099/jmm.0.000147.Rodriguez C.H., Nastro M., Vay C., Famiglietti A. In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. J Med Microbiol. 2015; 64 (10): 1196–1200. doi: 10.1099/jmm.0.000147.Yang,Y.S., Lee Y., Tsang K-C. et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016; 60 (7): 4047–54. doi: 10.1128/AAC.02994-15.Yang,Y.S., Lee Y., Tsang K-C. et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016; 60 (7): 4047–54. doi: 10.1128/AAC.02994-15.Ku N.S., Lee S-H., Lim Y-S. et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep. 2019; 9 (1): 17127. doi: 10.1038/s41598-019-53714-0.Ku N.S., Lee S-H., Lim Y-S. et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep. 2019; 9 (1): 17127. doi: 10.1038/s41598-019-53714-0.Bowers D.R., Cao H., Zhou J. et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59 (5): 2720–5. doi: 10.1128/AAC.04110-14.Bowers D.R., Cao H., Zhou J. et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59 (5): 2720–5. doi: 10.1128/AAC.04110-14.Qu X., et al. Polymyxin B combined with minocycline: a potentially effective combination against bla (OXA-23)-harboring CRAB in in vitro PK/PD model. Molecules. 2022; 27 (3): 1085. doi: 10.3390/molecules27031085.Qu X., et al. Polymyxin B combined with minocycline: a potentially effective combination against bla (OXA-23)-harboring CRAB in in vitro PK/PD model. Molecules. 2022; 27 (3): 1085. doi: 10.3390/molecules27031085.Beganovic M., Daffinee K.E., Luther M., LaPlante K. Minocycline alone and in combination with polymyxin b, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2021; 65 (3): e01680–20. doi: 10.1128/AAC.01680-20.Beganovic M., Daffinee K.E., Luther M., LaPlante K. Minocycline alone and in combination with polymyxin b, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2021; 65 (3): e01680–20. doi: 10.1128/AAC.01680-20.Lee Y.R., Burton C.E. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019; 38 (10): 1787–1794. doi: 10.1007/s10096-019-03590-3.Lee Y.R., Burton C.E. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019; 38 (10): 1787–1794. doi: 10.1007/s10096-019-03590-3.Solomkin J., Evans D., Slepavicius A., Lee P. et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017; 152 (3): 224–232. doi: 10.1001/jamasurg.2016.4237.Solomkin J., Evans D., Slepavicius A., Lee P. et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017; 152 (3): 224–232. doi: 10.1001/jamasurg.2016.4237.Solomkin J.S., Gardovskis J., Lawrence K. et al. IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019; 69 (6): 921–929. doi: 10.1093/cid/ciy1029.Solomkin J.S., Gardovskis J., Lawrence K. et al. IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019; 69 (6): 921–929. doi: 10.1093/cid/ciy1029.Alosaimy S., Morrisette T., Laghf A.M. et al. Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii. Microbiol Spectr. 2022; 10 (5): e0047922. doi: 10.1128/spectrum.00479-22.Alosaimy S., Morrisette T., Laghf A.M. et al. Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii. Microbiol Spectr. 2022; 10 (5): e0047922. doi: 10.1128/spectrum.00479-22.Seifert H., Stefanik D., Sutcliffe J.A., Higgins P.G. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018; 51 (1): 62–64. doi: 10.1016/j.ijantimicag.2017.06.022Seifert H., Stefanik D., Sutcliffe J.A., Higgins P.G. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018; 51 (1): 62–64. doi: 10.1016/j.ijantimicag.2017.06.022Galani I., Papoutsaki V., Karaiskos N. et al. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter study. Eur J Clin Microbiol Infect Dis. 2023; 42 (7): 843–852. doi: 10.1007/s10096-023-04616-7.Galani I., Papoutsaki V., Karaiskos N. et al. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter study. Eur J Clin Microbiol Infect Dis. 2023; 42 (7): 843–852. doi: 10.1007/s10096-023-04616-7.Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020; 64 (3): e01699–19. doi: 10.1128/AAC.01699-19.Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020; 64 (3): e01699–19. doi: 10.1128/AAC.01699-19.Kunz Coyne A.J., Alosaimy S., Lucas K. et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024; 12 (1): e0235123. doi: 10.1128/spectrum.02351-23.Kunz Coyne A.J., Alosaimy S., Lucas K. et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024; 12 (1): e0235123. doi: 10.1128/spectrum.02351-23.Ozger H.S., Cuhadar T., Yildiz S.S., Gulmez Z.D., Dizbay M., Tunccan O.G., Kalkanci A., Simsek H., Unaldi O. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J Antibiot (Tokyo). 2019; 72 (8): 600–604. doi: 10.1038/s41429-019-0188-6.Ozger H.S., Cuhadar T., Yildiz S.S., Gulmez Z.D., Dizbay M., Tunccan O.G., Kalkanci A., Simsek H., Unaldi O. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J Antibiot (Tokyo). 2019; 72 (8): 600–604. doi: 10.1038/s41429-019-0188-6.Li Y., Cui L., Xue F., Wang Q., Zheng B. Synergism of eravacycline combined with other antimicrobial agents against carbapenemresistant Enterobacteriaceae and Acinetobacter baumannii. J Glob Antimicrob Resist. 2022; 30: 56–59. doi: 10.1016/j.jgar.2022.05.020.Li Y., Cui L., Xue F., Wang Q., Zheng B. Synergism of eravacycline combined with other antimicrobial agents against carbapenemresistant Enterobacteriaceae and Acinetobacter baumannii. J Glob Antimicrob Resist. 2022; 30: 56–59. doi: 10.1016/j.jgar.2022.05.020.Scott C.J., Zhu E., Jayakumar R.A., Shan G., Viswesh V. Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii. Ann Pharmacother. 2022; 56 (12): 1299–1307. doi: 10.1177/10600280221085551.Scott C.J., Zhu E., Jayakumar R.A., Shan G., Viswesh V. Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii. Ann Pharmacother. 2022; 56 (12): 1299–1307. doi: 10.1177/10600280221085551.Dahesh S., Wong B., Nizet V., Sakolas G., Tran T.T., Aitken S.L. Treatment of multidrug-resistant vancomycin-resistant Enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin. Antimicrob Agents Chemother. 2019; 63 (7): e02622–18. doi: 10.1128/AAC.02622-18.Dahesh S., Wong B., Nizet V., Sakolas G., Tran T.T., Aitken S.L. Treatment of multidrug-resistant vancomycin-resistant Enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin. Antimicrob Agents Chemother. 2019; 63 (7): e02622–18. doi: 10.1128/AAC.02622-18.Nang S.C., Azad M.A.K., Velkov T., Zhou Q.T., Li J. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021; 73 (2): 679–728. doi: 10.1124/pharmrev.120.000020.Nang S.C., Azad M.A.K., Velkov T., Zhou Q.T., Li J. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021; 73 (2): 679–728. doi: 10.1124/pharmrev.120.000020.Rafailidis P., Panagopoulos P., Koutserimpas C., Samonis G. Current therapeutic approaches for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii Infections. Antibiotics (Basel). 2024; 13 (3): 261. doi: 10.3390/antibiotics13030261.Rafailidis P., Panagopoulos P., Koutserimpas C., Samonis G. Current therapeutic approaches for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii Infections. Antibiotics (Basel). 2024; 13 (3): 261. doi: 10.3390/antibiotics13030261.Huang C., Chen I., Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis. J Clin Med. 2022; 11 (11): 3239. doi: 10.3390/jcm11113239.Huang C., Chen I., Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis. J Clin Med. 2022; 11 (11): 3239. doi: 10.3390/jcm11113239.Shahzad S., Willcox M.D.P., Rayamajhee B. A review of resistance to polymyxins and evolving mobile colistin resistance gene (mcr) among pathogens of clinical significance. Antibiotics. 2023; 12 (11): 1597. doi: 10.3390/antibiotics12111597.Shahzad S., Willcox M.D.P., Rayamajhee B. A review of resistance to polymyxins and evolving mobile colistin resistance gene (mcr) among pathogens of clinical significance. Antibiotics. 2023; 12 (11): 1597. doi: 10.3390/antibiotics12111597.Martins-Sorenson N., Snesrud E., Xavier D.E. et al. A novel plasmid-encoded mcr-4.3 gene in a colistin-resistant Acinetobacter baumannii clinical strain. J Antimicrob Chemother. 2020; 75 (1): 60–64. doi: 10.1093/jac/dkz413.Martins-Sorenson N., Snesrud E., Xavier D.E. et al. A novel plasmid-encoded mcr-4.3 gene in a colistin-resistant Acinetobacter baumannii clinical strain. J Antimicrob Chemother. 2020; 75 (1): 60–64. doi: 10.1093/jac/dkz413.Кузьменков А.Ю., Виноградова А.Г., Трушин И.В., Эйдельштейн М.В., Авраменко А.А., Дехнич А.В., Козлов Р.С. AMRMAP — cистема мониторинга антибиотикорезистентности в России. Клиническая микробиология и антимикробная химиотерапия. 2021; 23 (2): 198–204.Kuz'menkov A.Jyu., Vinogradova A.G., Trushin I.V., Ejdel'shtejn M.V., Avramenko A.A., Dekhnich A.V., Kozlov R.S. AMRMAP — sistema monitoringa antibiotikorezistentnosti v Rossii. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2021; 23 (2): 198–204. (in Russian)Tsuji B.T., Pogue J.M., Zavascki A.P. et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39 (1): 10–39. doi: 10.1002/phar.2209.Tsuji B.T., Pogue J.M., Zavascki A.P. et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39 (1): 10–39. doi: 10.1002/phar.2209.Kaye K.S., Marchaim D., Thamlikitkul V. et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023; 2 (1): 10.1056/evidoa2200131. doi: 10.1056/evidoa2200131.Kaye K.S., Marchaim D., Thamlikitkul V. et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023; 2 (1): 10.1056/evidoa2200131. doi: 10.1056/evidoa2200131.Wei W., Yang H., Liu Y., Ye Y., Li J. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother. 2016; 28 (3): 159–163. doi: 10.1179/1973947815Y.0000000030.Wei W., Yang H., Liu Y., Ye Y., Li J. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother. 2016; 28 (3): 159–163. doi: 10.1179/1973947815Y.0000000030.Qureshi Z.A., Hittle L., O'Hara J.A. et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015; 60 (9): 1295–1303. doi: 10.1093/cid/civ048.Qureshi Z.A., Hittle L., O'Hara J.A. et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015; 60 (9): 1295–1303. doi: 10.1093/cid/civ048.Zhang J., Song C., Wu M. et al. Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii. Eur J Pharm Sci. 2023; 185: 106443. doi: 10.1016/j.ejps.2023.106443.Zhang J., Song C., Wu M. et al. Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii. Eur J Pharm Sci. 2023; 185: 106443. doi: 10.1016/j.ejps.2023.106443.Park H.J., Cho J.H., Kim H.J., Han S.H., Jeong S.H., Byun M.K. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019; 17: 66–71. doi: 10.1016/j.jgar.2018.11.016.Park H.J., Cho J.H., Kim H.J., Han S.H., Jeong S.H., Byun M.K. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019; 17: 66–71. doi: 10.1016/j.jgar.2018.11.016.Karruli A., Migliaccio A., Pournaras S., Durante–Mangoni E., Zarrilli R. Cefiderocol and sulbactam–durlobactam against carbapenem-resistant Acinetobacter baumannii. Antibiotics (Basel). 2023; 12 (12): 1729. doi: 10.3390/antibiotics12121729.Karruli A., Migliaccio A., Pournaras S., Durante–Mangoni E., Zarrilli R. Cefiderocol and sulbactam–durlobactam against carbapenem-resistant Acinetobacter baumannii. Antibiotics (Basel). 2023; 12 (12): 1729. doi: 10.3390/antibiotics12121729.Sato T., Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019; 69 (Suppl 7): S538–S543. doi: 10.1093/cid/ciz826.Sato T., Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019; 69 (Suppl 7): S538–S543. doi: 10.1093/cid/ciz826.Karakonstantis S., Rousaki M., Kritsotakis E.I. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics (Basel). 2022; 11 (6): 723. doi: 10.3390/antibiotics11060723.Karakonstantis S., Rousaki M., Kritsotakis E.I. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics (Basel). 2022; 11 (6): 723. doi: 10.3390/antibiotics11060723.Smoke S.M., Brophy A., Reveron S. et al. Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit. Clin Infect Dis. 2023; 76 (3): e1261–e1265. doi: 10.1093/cid/ciac647.Smoke S.M., Brophy A., Reveron S. et al. Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit. Clin Infect Dis. 2023; 76 (3): e1261–e1265. doi: 10.1093/cid/ciac647.Malik S., Kaminski M., Landman D., Quale J. Cefiderocol resistance in Acinetobacter baumannii: roles of beta-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob Agents Chemother. 2020; 64 (11): e01221–20. doi: 10.1128/AAC.01221-20.Malik S., Kaminski M., Landman D., Quale J. Cefiderocol resistance in Acinetobacter baumannii: roles of beta-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob Agents Chemother. 2020; 64 (11): e01221–20. doi: 10.1128/AAC.01221-20.Karlowsky J.A., Hackel M.A., Takemura M., Yamano Y., Echols R., Sahm D.F. In vitro susceptibility of gram-negative pathogens to Cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother. 2022; 66 (2): e0199021. doi: 10.1128/AAC.01990-21.Karlowsky J.A., Hackel M.A., Takemura M., Yamano Y., Echols R., Sahm D.F. In vitro susceptibility of gram-negative pathogens to Cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother. 2022; 66 (2): e0199021. doi: 10.1128/AAC.01990-21.Bassetti M., Echols R., Matsunaga Y. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021; 21 (2): 226–240. doi: 10.1016/S1473-3099(20)30796-9.Bassetti M., Echols R., Matsunaga Y. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021; 21 (2): 226–240. doi: 10.1016/S1473-3099(20)30796-9.Wunderink R.G., Matsunaga Y., Ariyasu M. et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021; 21 (2): 213–225. doi: 10.1016/S1473-3099(20)30731-3.Wunderink R.G., Matsunaga Y., Ariyasu M. et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021; 21 (2): 213–225. doi: 10.1016/S1473-3099(20)30731-3.Falcone M., Tiseo G., Leonidi A, Sala L., Vecchione A., Barnini S., Farcomeni A., Menichetti F. Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022; 66 (5): e0214221. doi: 10.1128/aac.02142-21.Falcone M., Tiseo G., Leonidi A, Sala L., Vecchione A., Barnini S., Farcomeni A., Menichetti F. Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022; 66 (5): e0214221. doi: 10.1128/aac.02142-21.Russo A., Bruni A., Borrazzo C. et al. Efficacy of cefiderocol — vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023; 62 (1): 106825. doi: 10.1016/j.ijantimicag.2023.106825.Russo A., Bruni A., Borrazzo C. et al. Efficacy of cefiderocol — vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023; 62 (1): 106825. doi: 10.1016/j.ijantimicag.2023.106825.Onorato L., de Luca I., Monari C., Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. J Infect. 2024; 88 (3): 106113. doi: 10.1016/j.jinf.2024.01.012.Onorato L., de Luca I., Monari C., Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. J Infect. 2024; 88 (3): 106113. doi: 10.1016/j.jinf.2024.01.012.Gill C.M., Santini D., Takemura M., Longshaw C., Yamano Y., Echols R., Nicolau D. In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. 2023; 78 (4): 983–990. doi: 10.1093/jac/dkad032.Gill C.M., Santini D., Takemura M., Longshaw C., Yamano Y., Echols R., Nicolau D. In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. 2023; 78 (4): 983–990. doi: 10.1093/jac/dkad032.Lim J.S., Chai Y-Y., Ser W-X. et al. Novel drug candidates against antibiotic-resistant microorganisms: A review. Iran J Basic Med Sci. 2024; 27 (2): 134–150. doi: 10.22038/IJBMS.2023.71672.15593.Lim J.S., Chai Y-Y., Ser W-X. et al. Novel drug candidates against antibiotic-resistant microorganisms: A review. Iran J Basic Med Sci. 2024; 27 (2): 134–150. doi: 10.22038/IJBMS.2023.71672.15593.Plattner M., Gysin M., Haldimann K., Becker K., Hobbie S. Epidemiologic, phenotypic, and structural characterization of aminoglycosideresistance gene aac (3)-IV. Int J Mol Sci. 2020; 21 (17): 6133. doi: 10.3390/ijms21176133.Plattner M., Gysin M., Haldimann K., Becker K., Hobbie S. Epidemiologic, phenotypic, and structural characterization of aminoglycosideresistance gene aac (3)-IV. Int J Mol Sci. 2020; 21 (17): 6133. doi: 10.3390/ijms21176133.Juhas M., Widlake E., Teo J., Huseby D. et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019; 74 (4): 944–952. doi: 10.1093/jac/dky546.Juhas M., Widlake E., Teo J., Huseby D. et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019; 74 (4): 944–952. doi: 10.1093/jac/dky546.Galani I., Souli M., Katsala D., Karaiskos I., Giamarellou H., Antoniadou A. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. J Antimicrob Chemother. 2024; 79 (5): 1101–1108. doi: 10.1093/jac/dkae077.Galani I., Souli M., Katsala D., Karaiskos I., Giamarellou H., Antoniadou A. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. J Antimicrob Chemother. 2024; 79 (5): 1101–1108. doi: 10.1093/jac/dkae077.Duncan L.R., Wang W., Sader H.S. In vitro potency and spectrum of the novel polymyxin MRX-8 tested against clinical isolates of gram-negative bacteria. Antimicrob Agents Chemother; 2022; 66 (5): e0013922. doi: 10.1128/aac.00139-22.Duncan L.R., Wang W., Sader H.S. In vitro potency and spectrum of the novel polymyxin MRX-8 tested against clinical isolates of gram-negative bacteria. Antimicrob Agents Chemother; 2022; 66 (5): e0013922. doi: 10.1128/aac.00139-22.Buchwald P. Soft drugs: design principles, success stories, and future perspectives. Expert Opin Drug Metab Toxicol. 2020; 16 (8): 645–650. doi: 10.1080/17425255.2020.1777280.Buchwald P. Soft drugs: design principles, success stories, and future perspectives. Expert Opin Drug Metab Toxicol. 2020; 16 (8): 645–650. doi: 10.1080/17425255.2020.1777280.Wu S., Yin D., Zhi P., Guo Y., Yang Y., Zhu D., Hu F. In vitro activity of MRX-8 and comparators against clinical isolated gram-negative bacilli in China. Front Cell Infect Microbiol. 2022; 12: 829592.Wu S., Yin D., Zhi P., Guo Y., Yang Y., Zhu D., Hu F. In vitro activity of MRX-8 and comparators against clinical isolated gram-negative bacilli in China. Front Cell Infect Microbiol. 2022; 12: 829592.Qu X., Guo C., Liu S., Li X., Liu X., Zhang J. Pharmacokinetics and nephrotoxicity of polymyxin MRX-8 in rats: a novel agent against resistant gram-negative bacteria. Antibiotics (Basel). 2024; 13 (4): 354. doi: 10.3390/antibiotics13040354.Qu X., Guo C., Liu S., Li X., Liu X., Zhang J. Pharmacokinetics and nephrotoxicity of polymyxin MRX-8 in rats: a novel agent against resistant gram-negative bacteria. Antibiotics (Basel). 2024; 13 (4): 354. doi: 10.3390/antibiotics13040354.Li L., Tan X., Zhou T., Chi S., Zhu Y., Liu Q., Chen Y., Zhang J. In vivo efficacy and PK/PD analyses of zifanocycline (KBP-7072), an aminomethylcycline antibiotic, against Acinetobacter baumannii in a neutropenic murine thigh infection model. J Infect Chemother. 2024; 30 (1): 34–39. doi: 10.1016/j.jiac.2023.09.010.Li L., Tan X., Zhou T., Chi S., Zhu Y., Liu Q., Chen Y., Zhang J. In vivo efficacy and PK/PD analyses of zifanocycline (KBP-7072), an aminomethylcycline antibiotic, against Acinetobacter baumannii in a neutropenic murine thigh infection model. J Infect Chemother. 2024; 30 (1): 34–39. doi: 10.1016/j.jiac.2023.09.010.Han R., Ding L., Yang Y. et al. In vitro activity of KBP-7072 against 536 Acinetobacter baumannii complex isolates collected in China. Microbiol Spectr 2022; 10 (1): e0147121. doi: 10.1128/spectrum.01471-21.Han R., Ding L., Yang Y. et al. In vitro activity of KBP-7072 against 536 Acinetobacter baumannii complex isolates collected in China. Microbiol Spectr 2022; 10 (1): e0147121. doi: 10.1128/spectrum.01471-21.Huband M.D., Mendes R.E., Pfaller M.A. et al. In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. Antimicrob Agents Chemother. 2020; 64 (5): e02375–19. doi: 10.1128/AAC.02375-19.Huband M.D., Mendes R.E., Pfaller M.A. et al. In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. Antimicrob Agents Chemother. 2020; 64 (5): e02375–19. doi: 10.1128/AAC.02375-19.Zampaloni C., Mattei P., Bleicher K. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024; 625 (7995): 566–571. doi: 10.1038/s41586-023-06873-0.Zampaloni C., Mattei P., Bleicher K. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024; 625 (7995): 566–571. doi: 10.1038/s41586-023-06873-0.Hawser S., Kothari N., Valmont T., Louvel S. Activity of the novel antibiotic zosurabalpin (RG6006) against clinical acinetobacter isolates from China, in open forum infectious diseases. 2023; 5897–5898.Hawser S., Kothari N., Valmont T., Louvel S. Activity of the novel antibiotic zosurabalpin (RG6006) against clinical acinetobacter isolates from China, in open forum infectious diseases. 2023; 5897–5898.

The authors declare that there are no conflicts of interest present.